SCHEMBL4001602

SCHEMBL4001602

NCCCCOCCCCN

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 1/20 0.54
DNM1 Q05193 6/20 0.50
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA3 P07451 2/20 0.50
CA4 P22748 2/20 0.50
CA6 P23280 2/20 0.50
CA5A P35218 2/20 0.50
CA7 P43166 2/20 0.50
CA9 Q16790 2/20 0.50
CA14 Q9ULX7 2/20 0.50
CA5B Q9Y2D0 2/20 0.50
TSHR P16473 2/20 0.50
LMNA P02545 1/20 0.50
BLM P54132 1/20 0.50
ODC1 P11926 1/20 0.44
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3996459 1.00 NFKB1 (0.54) NFKB1DNM1CA12CA1CA2
SCHEMBL2050536 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL21357594 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL8746964 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL1726884 0.96 NFKB1 (0.50) NFKB1DNM1CA12CA1CA2
SCHEMBL24306534 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL11236971 0.96 NFKB1 (0.50) NFKB1DNM1CA12CA1CA2
Hydrochloric Acid SCHEMBL16030749 0.96 NFKB1 (0.50) NFKB1DNM1CA12CA1CA2
SCHEMBL8746941 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2
SCHEMBL6049174 0.96 DNM1 (0.57) NFKB1DNM1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570890-B2 Additives for well treatment, methods for preparing well treatment composition using these additives, and applications of said composition CAMERON INTERNATIONAL CORPORATION (US) 2026-03-10 US claimed
US-20250297153-A1 ADDITIVES FOR WELL TREATMENT, METHODS FOR PREPARING WELL TREATMENT COMPOSITION USING THESE ADDITIVES, AND APPLICATIONS OF SAID COMPOSITION CAMERON INTERNATIONAL CORPORATION 2025-09-25 US claimed
EP-4526395-A1 ADDITIVES FOR WELL TREATMENT, METHODS FOR PREPARING WELL TREATMENT COMPOSITION USING THESE ADDITIVES, AND APPLICATIONS OF SAID COMPOSITION Cameron Technologies Limited (NL) 2025-03-26 EP claimed
CN-119256064-A Additives for well treatment, methods of preparing well treatment compositions using these additives, and uses of the compositions 卡梅伦技术有限公司 2025-01-03 CN claimed
WO-2023224967-A1 ADDITIVES FOR WELL TREATMENT, METHODS FOR PREPARING WELL TREATMENT COMPOSITION USING THESE ADDITIVES, AND APPLICATIONS OF SAID COMPOSITION CAMERON INTERNATIONAL CORPORATION (US) 2023-11-23 WO claimed
US-12570890-B2 Additives for well treatment, methods for preparing well treatment composition using these additives, and applications of said composition CAMERON INTERNATIONAL CORPORATION (US) 2026-03-10 US disclosed
US-12479840-B2 HMG-CoA reductase degradation inducing compound UPPTHERA INC. (KR) 2025-11-25 US disclosed
US-20250297153-A1 ADDITIVES FOR WELL TREATMENT, METHODS FOR PREPARING WELL TREATMENT COMPOSITION USING THESE ADDITIVES, AND APPLICATIONS OF SAID COMPOSITION CAMERON INTERNATIONAL CORPORATION 2025-09-25 US disclosed
EP-4526395-A1 ADDITIVES FOR WELL TREATMENT, METHODS FOR PREPARING WELL TREATMENT COMPOSITION USING THESE ADDITIVES, AND APPLICATIONS OF SAID COMPOSITION Cameron Technologies Limited (NL) 2025-03-26 EP disclosed
CN-119256064-A Additives for well treatment, methods of preparing well treatment compositions using these additives, and uses of the compositions 卡梅伦技术有限公司 2025-01-03 CN disclosed
WO-2023224967-A1 ADDITIVES FOR WELL TREATMENT, METHODS FOR PREPARING WELL TREATMENT COMPOSITION USING THESE ADDITIVES, AND APPLICATIONS OF SAID COMPOSITION CAMERON INTERNATIONAL CORPORATION (US) 2023-11-23 WO disclosed
EP-4279494-A1 METHOD FOR DECOMPOSING COMPOUND, AND COMPOUND National University Corporation Hokkaido University (JP) 2023-11-22 EP disclosed
EP-0042940-B1 HETEROALKYLENE-BIS-ANTHRAQUINONES AMERICAN CYANAMID COMPANY (US) 1984-06-06 EP disclosed
EP-0030822-B1 SYNTHETIC ABSORBABLE SURGICAL DEVICES OF POLYESTER AMIDES AND PROCESS FOR MAKING THEM MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1983-09-14 EP disclosed
EP-0078436-A1 Non-crystalline polyamine/carbonic-acid salt compostions, process for their preparation and their use in making polyurethane-polyureas, particularly foamed coatings BAYER AG (DE) 1983-05-11 EP disclosed
US-4343931-A FILAMENTS, SUTURES, PROSTHETICS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1982-08-10 US disclosed
EP-0042940-A1 Heteroalkylene-bis-anthraquinones AMERICAN CYANAMID COMPANY (US) 1982-01-06 EP disclosed
US-4278605-A ANTITUMOR AGENTS AMERICAN CYANAMID COMPANY (US) 1981-07-14 US disclosed
EP-0030822-A2 Synthetic absorbable surgical devices of polyester amides and process for making them MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1981-06-24 EP disclosed
US-3994882-A ANTIMICROBIAL KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO (JA) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570890-B2 Additives for well treatment, methods for preparing well treatment composition using these additives, and applications of said composition ATM, PWWP2B, AQP3 NFKB1 3127/4885DNM1 4872/4885CA12 1524/4885
US-12479840-B2 HMG-CoA reductase degradation inducing compound HMGCR, HMGB2, LDLR NFKB1 677/4885DNM1 1523/4885CA12 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.